Acadia Pharmaceuticals (ACAD) announced that the FDA has approved Daybue Stix for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is expected to deliver the same efficacy and safety profile of Daybue oral solution, while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their Daybue treatment.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
- Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho
- Acadia Pharmaceuticals price target lowered to $31 from $33 at JPMorgan
- ACADIA Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights